Personalized CRISPR therapies could soon reach thousands — here’s how

In February, the US Food and Drug Administration (FDA) proposed a radical rethink of how scientists, physicians and manufacturers develop personalized genetic therapies. The regulator’s suggested introduction of a ‘plausible mechanism pathway’ should increase incentives for drug companies to develop personalized treatments, including gene-editing therapies for rare disorders (see go.nature.com/4mnmgzq). The baby whose life was…

Read More